Molecule fights cancer on two fronts
Researchers at the University of Leeds have made a new synthetic anti-cancer molecule that targets two key mechanisms in the spread of malignant tumours through the body.
Nov 13, 2014
0
0
Researchers at the University of Leeds have made a new synthetic anti-cancer molecule that targets two key mechanisms in the spread of malignant tumours through the body.
Nov 13, 2014
0
0
A molecule that helps cancer cells evade programmed self-destruction, an internal source of death, might also help malignant cells hide from the immune system, an external source of death.
Oct 7, 2014
0
0
(Medical Xpress)—New research led by scientists at The University of Texas Health Science Center at Houston (UTHealth) and Baylor College of Medicine could aid efforts to diagnose and treat one of the most lethal and hard-to-treat ...
Aug 22, 2013
0
0
Prostate cancer is one of the most common forms of cancer in men and the leading cause of cancer deaths in white, African-American and Hispanic men, according to the Centers for Disease Control. Current treatment of prostate ...
Aug 20, 2013
0
0
Human glioblastoma multiforme, one of the most common, aggressive and deadly forms of brain cancer, is notoriously difficult to study. Scientists have traditionally studied cancer cells in petri dishes, which have none of ...
Jul 23, 2013
0
0
Proteins that control cell growth are often mutated in cancer, and their aberrant signaling drives the wild proliferation of cells that gives rise to tumors. One such protein, the epidermal growth factor receptor (EGFR), ...
Apr 8, 2013
0
1
The novel c-MET and VEGFR2 inhibitor, XL-184 (Cabozantinib), resulted in a significant decrease in tumor growth in 12 out of 12 colorectal cancer (CRC) patient-derived explants, with 8 of the explants exhibiting stable disease. ...
Apr 8, 2013
0
0
Researchers at Moffitt Cancer Center have determined that the overexpression of microRNA-155 (miR-155), a short, single strand of ribonucleic acid encoded by the miR-155 host gene, promotes the growth of blood vessels in ...
Apr 3, 2013
0
1
Researchers at Moffitt Cancer Center have completed a phase II clinical trial to determine the safety and efficacy of dasatinib for patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia, ...
Mar 21, 2013
0
0
(Medical Xpress)—One of the hallmarks of cancer is unchecked cellular growth. Fortunately, our cells contain a number of tumor suppressor proteins, including the cell cycle regulator p21, to keep cell growth in check. The ...
Feb 13, 2013
0
0